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LETTER TO THE EDITOR Open Access
High applicability of ASO-RQPCR for
detection of minimal residual disease
in multiple myeloma by entirely
patient-specific primers/probes
Yinlei Bai, Kwan Yeung Wong, Tsz Kin Fung and Chor Sang Chim*
Abstract
Allele-specific oligonucleotide real-time quantitative PCR (ASO-RQPCR) is a standardized technique for detection
and monitoring of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) but not multiple myeloma
(MM) due to a low applicability inherent with presence of somatic hypermutation. Herein, by a staged PCR
approach and sequencing, clonality and tumor-specific complementarity-determining region 3 (CDR3) sequence
were identified in 13/13 MM by sequential PCR of IgH VDJ (n = 10), IgH DJ (n = 2), or IgK VJ (n = 1). Using consensus
primers/probes conventionally employed in ALL, ASO-RQPCR worked in three (23.1 %) cases only. Conversely, using
entirely patient-specific primers/probes, ASO-RQPCR was applicable in eight (61.5 %) cases with a sensitivity of
5 × 10−4–10−5. Moreover, using standard curves constructed by serial dilution of plasmids cloned with patient-specific
CDR3, ASO-RQPCR was successful in 12 (92.3 %) cases with a sensitivity of 10−4–10−5, but not in a case lacking an N
region, in which design of a tumor-specific ASO primer was precluded. Finally, in a patient in complete response (CR),
further reduction of MRD after autologous stem cell transplantation (ASCT) was demonstrated. In summary, using
entirely patient-specific primers/probes, ASO-RQPCR was applicable in >90 % MM patients and enabled detection of
dynamic changes of MRD before and after ASCT despite conventional CR.
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Letter to the editor
Minimal residual disease (MRD) in multiple myeloma
(MM) may be studied by allele-specific oligonucleotide
real-time quantitative PCR (ASO-RQPCR), first ap-
plied in acute lymphoblastic leukemia (ALL) using
patient-specific ASO forward primers derived from
complementarity-determining region 3 (CDR3) sequences
of immunoglobulin (Ig) genes [1], combined with consen-
sus reverse germline primers and TaqMan probes in the
JH region [2]. While applicable in >90 % ALL [3], the con-
sensus primers/probes are only applicable in 42–75 %
MM due to somatic hypermutations [4, 5].
Herein, in 13 consecutive MM (Additional file 1:
Table S1), clonality and sequence of CDR3 were identi-
fied in diagnostic BM of all 13 (100 %) cases by a staged
PCR approach, involving sequential PCR of IgH VDJ,
IgH DJ, and IgK VJ rearrangements (Additional file 2:
Figure S1; Table S2), superior to studies using
BIOMED-2 multiplex PCR [4, 5]. Clonality was identi-
fied in three (23.1 %) cases by FR3 IgH VDJ PCR, seven
(53.8 %) by FR1 IgH VDJ PCR, two (15.4 %) by IgH DJ
PCR, and one (7.7 %) by IgK VJ PCR. Similar to previous
MM studies [5–7], VH1, VH3, and VH4 families were
mostly used (12~19 %, 47~63 %, and 16~20 %, res-
pectively) (Additional file 2: Table S3).
ASO-RQPCR was first performed using ASO forward
primers and consensus primers/probes, according to the
EuroMRD guidelines (Additional file 2: Figure S2; Table S2)
[2, 8, 9]. By standard curves serially diluted from diagnostic
BM, ASO-RQPCR was applicable in only three (23.1 %)
cases, with a sensitivity of 5 × 10−4–10–4 and a quantitative
range (QR) of 10−3–10−4 (Table 1), suggestive of MRD
quantification in follow-up samples with one myeloma cell
* Correspondence: jcschim@hku.hk
Department of Medicine, Queen Mary Hospital, The University of Hong Kong,
Pokfulam, Hong Kong
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bai et al. Journal of Hematology & Oncology  (2016) 9:107 
DOI 10.1186/s13045-016-0336-4
in a background of 104 normal cells [10]. Causes of failures
in other cases included absence of amplification (n = 5) or
non-specific amplification in normal control (n = 1) during
preliminary qualitative PCR, suboptimal QR of 10−2 (n = 3),
or shortage of diagnostic BM for standard curve (n = 1).
To account for a low applicability using consensus
primers/probes, a systematic search for sequences mis-
matches against consensus primers/probes was per-
formed. Sequencing data revealed mismatches in five
(50 %) cases against consensus primers, six (50 %)
against probes, and two (20 %) against both sites, but
not in two IgH cases (M7 and M10) or one IgK case
(M9) (Table 2). While a previous MM study also showed
a high frequency of mismatches against consensus
primers/probes in patients with IgH VDJ rearrange-
ments (herein 80 vs. 75 %), the number of mismatches
per case was higher in our study (five vs. three) [11].
Given that mismatches of ≥3 bases would preclude a
successful ASO-RQPCR [11], the use of patient-specific
primers/probes is inevitable in Chinese MM with pro-
found mismatches than Caucasian patients.
Therefore, ASO-RQPCR using entirely patient-specific
primers/probes was performed (Additional file 2: Figure S2;
Table S4). Except one case (M2) amplified by IgH DJ PCR,
Table 1 Performance of RQPCR by consensus germline or entirely patient-specific primers/probes
Cases Consensus germline primers/probes Patient-specific primers/probes
Diagnostic marrow DNA as standards Diagnostic marrow DNA as standards CDR3-cloned plasmid as standards
Sensitivity QR R2 Slope Sensitivity QR R2 Slope Sensitivity QR R2 Slope
Dx53 N/A 10−2 N/A N/A 10−5 10−4 0.996 −3.30 10−5 10−4 0.992 −3.44
M3 ND ND ND ND 5 × 10−4 5 × 10−4 0.989 −3.48 10−4 10−4 0.997 −3.54
M8 10−4 5 × 10−4 0.985 −3.38 10−4 10−3 0.999 −3.46 10−4 5 × 10−4 0.999 −3.61
M4 ND ND ND ND 10−4 10−3 0.984 −3.60 10−5 10−3 0.999 −3.54
Dx31 ND ND ND ND 10−4 5 × 10−4 0.998 −3.45 10−4 10−4 0.998 −3.47
M5 10−4 10−4 0.995 −3.41 5 × 10−4 5 × 10−4 0.995 −3.67 10−5 10−4 0.998 −3.51
M10 N/A 5 × 10−4 N/A N/A N/A 5 × 10−4 N/A N/A 10−4 10−4 0.994 −3.51
Dx49 5 × 10−4 10−3 0.982 −3.37 10−4 10−3 0.986 −3.26 10−4 5 × 10−4 0.999 −3.76
M1 ND ND ND ND 5 × 10−4 10−3 0.986 −3.48 10−4 5 × 10−4 0.998 −3.52
M6 ND ND ND ND N/A 5 × 10−4 N/A N/A 10−5 5 × 10−4 0.997 −3.72
M2 N/A N/A N/A N/A ND ND ND ND ND ND ND ND
M7 N/A 10−2 N/A N/A N/A 10−2 N/A N/A 10−4 10−3 0.999 −3.56
M9 N/A 10−2 N/A N/A N/A 10−2 N/A N/A 10−4 10−4 0.997 −3.55
Abbreviations: QR quantitative range, R2 correlation coefficient, N/A not applicable, ND not done due to absence of target band in qualitative PCR or no need
(for M2 in patient-specific approach)
Table 2 Mismatches against consensus germline reverse primers and/or probes
Cases Mismatches against primers Mismatches against probes
Primers Primer binding site sequences No. Probes Probe binding site sequences No.
Dx53 R-JH6-intron gcagaGaGGaaGggccctagagt 4 T-JH6 cacggtcaccgtctcctcaggCaagaa 1
M3 R-JH4-intron cagagAAaaTATCACagagaggttgt 8 T-JH1.2.4.5 ccctggtcaccgtctcctcaggtg 0
M8 R-JH4-intron cagagCtaaagcaggagagaggttgt 1 T-JH1.2.4.5 ccctggtcaccgtctcctcaggtg 0
M4 R-JH4-intron cagGAttTaagTaggGgagaCgttgt 6 T-JH1.2.4.5 ccctggtcaccgtctcctcaggtg 0
Dx31 R-JH4-intron TagaCCCaaagTaggagagaCAttAt 8 T-JH1.2.4.5 Tcctggtcaccgtctcctcaggtg 1
M5 R-JH3-intron aggcagaaggaaagccatcttac 0 T-JH3 cCagggacaatggtcaccgtctcttca 1
M10 R-JH6-intron gcagaaaacaaaggccctagagt 0 T-JH6 cacggtcaccgtctcctcaggtaagaa 0
Dx49 R-JH6-intron – ? T-JH6 cacggtcaccgtctcctcaggtaagaT 1
M1 R-JH4-intron – ? T-JH1.2.4.5 cTGt— ≥2
M6 R-JH3-intron – ? T-JH3 caagggacaat— ?
M2 R-JH4-intron cagagttaaagcaggagagaggttgt 0 T-JH1.2.4.5 ccctggtcGccgtctcctcaggtg 1
M7 R-JH5-intron agagagggggtggtgaggact 0 T-JH1.2.4.5 ccctggtcaccgtctcctcaggtg 0
M9 R-Jk1 gatcacttcatagacacagggaacag 0 T-Jk1 tggaaatcaaacgtgag 0
Uppercase letters in sequences indicate mismatches. “?” indicates mismatches cannot be identified based on available sequencing data
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where the absence of an N region precluded design of a
specific ASO primer, patient-specific primers/probes ASO-
RQPCR was successful in eight (61.5 %) cases (Table 1).
Moreover, as diagnostic BM was limited, we attempted
to construct standard curves by plasmid DNA cloned
with patient-specific CDR3, whereby ASO-RQPCR was
applicable in all 12 cases, with a sensitivity of ≤10−4 in
all 12 (100 %) cases and a QR ≤5 × 10−4 in ten (83.3 %)
cases (Table 1). Collectively, using CDR3-cloned plasmid
DNA, more cases achieved a sensitivity of ≤10−4 than
using diagnostic BM (12 vs. 5 cases: p = 0.0046; Table 1),
and applicability was increased from 61.5 to 92.3 %.
Moreover, plasmid DNA provides an unlimited supply
for standard curve construction in multiple MRD ana-
lysis. Furthermore, the use of plasmid DNA is more ac-
curate for cases in which the percentage of plasma cells
was not specified in the diagnostic BM.
Finally, in a patient (Dx53) who achieved serological
complete response (CR) after four cycles of VTD induc-
tion, by ASO-RQPCR with a sensitivity of 10−5 and QR
of 10−4, MRD was present in both BM samples on days
120 and 16 prior to autologous stem cell transplantation
(ASCT), but turned negative on day 14 after ASCT,
testifying further reduction of tumor load below clinical
detection limit by ASCT (Additional file 2: Figure S3).
In summary, a high applicability and sensitivity of MRD
detection by ASO-RQPCR can be achieved by clonality
detection using stepwise PCR approach, mismatch ana-
lysis, and hence entirely patient-specific primers/probes in
addition to standard curve construction using CDR3-
cloned plasmid DNA. Moreover, the use of ASCT in a
patient achieving serological CR after induction was
justified by further reduction of tumor load illustrated
by ASO-RQPCR. Finally, the frequency and intensity of
mismatches against consensus primers/probes between
different populations warrants further study in an ex-
panded cohort.
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